Crossmark

An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study

Crossref DOI link: https://doi.org/10.1186/s13023-022-02405-7

Published Online: 2022-07-09

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Richards, Duncan

Millns, Helen

Cookson, Louise

Lukas, Mary Ann https://orcid.org/0000-0003-0791-5580
Funding

Funding for this research was provided by:

GlaxoSmithKline (GSK (Study 115970))
License Information

Text and Data Mining valid from 2022-07-09

Version of Record valid from 2022-07-09
More Information

Article History

Received: 8 December 2021

Accepted: 26 June 2022

First Online: 9 July 2022

Declarations

:

: The study protocol, any amendments, the informed consent, and other information that required pre-approval were reviewed and approved by a single investigational ethics committee (Wales Research Ethics Committee, Cardiff, UK), in accordance with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice and applicable country-specific requirements. Written informed consent was obtained from each patient.

: Not applicable.

: HM, LC and MAL are employees of and hold stocks/shares in GSK. DR was an employee of GSK at the time of study conduct.

Document is current

Any future updates will be listed below